Researchers at the University of Arizona are leading efforts to image the molecular compositions of tumors in patients with cancer, to improve cancer diagnoses and evaluate the earliest responses to cancer treatment.
Personalized Medical Imaging
The Contrast Agent Molecular Engineering Laboratory (CAMEL) develops chemical agents that change the contrast of biomedical images. These contrast agents are designed to respond to molecular biomarkers of biological processes and pathologies. This molecular information is used to predict response to therapy before the therapy is applied, monitor the delivery of therapy to targeted tissues, and evaluate the early-stage effects of the therapy. These diagnostic methods that affect the choice of therapy are designed to provide personalized medicine for each individual patient.